Cipla has informed that further to the press release submitted by the Company on 10th December 2023, It was brought to attention by US FDA that there was information in its risk assessment that was not pertinent to this product. As a result the company reissued a revised press release Voluntary Nationwide Recall of one lot of Vigabatrin for Oral Solution, USP 500mg due to leaking sachets by InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company in USA.
The above information is a part of company’s filings submitted to BSE.
